Zinplava (bezlotoxumab) Disease Interactions
There are 2 disease interactions with Zinplava (bezlotoxumab):
Bezlotoxumab (applies to Zinplava) CHF
Major Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure
Heart failure was reported more frequently with bezlotoxumab than with placebo in two Phase 3 clinical trials, and occurred primarily in patients with underlying congestive heart failure (CHF). In patients with a history of CHF, 12.7% (15/118) of bezlotoxumab-treated patients and 4.8% (5/104) of placebo-treated patients had heart failure as an adverse reaction during the 12-week study period, and 19.5% (23/118) versus 12.5% (13/104) died, respectively. The causes of death varied and included cardiac failure, infections, and respiratory failure. Therapy with bezlotoxumab should be reserved for use only when the benefit outweighs the risk in patients with a history of CHF.
Bezlotoxumab (applies to Zinplava) congestive heart failure
Moderate Potential Hazard, Moderate plausibility.
Bezlotoxumab should be used with caution in patients with a history of congestive heart failure, and it should be reserved for use when the benefits outweigh the risk.
More about Zinplava (bezlotoxumab)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Pricing & Coupons
- En Español
- Drug class: immune globulins
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|